Inflammatory bowel disease

These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

For Colitis and Crohn’s Disease Awareness Week, learn about the challenges of this painful condition—and why Johnson & Johnson continues to seek new treatment options.

Sid Jain, a leader on the pharmaceutical R&D data science team at Johnson & Johnson, knows that new and better treatment options change lives. And being a Crohn’s disease patient himself has supercharged his mission to help revolutionize the research process.

What do diseases like multiple myeloma and lupus have in common? They’re more prevalent in people of color—yet historically these patients have been left out of clinical research, often to dire health consequences. Learn how Johnson & Johnson is working to make the study of conditions like these more equitable.

Over the past few decades, advances in the study and treatment of this inflammatory bowel disease have rapidly accelerated. We spoke to the experts to learn the latest about managing Crohn’s disease—and what other potential breakthroughs are on the horizon.

A groundbreaking trial for an HIV vaccine. New ways to help the body heal itself. Immunotherapy treatments for cancer. Behind medical advancements like these are the brilliant scientists who are relentlessly pushing their visions and research forward.

There are trillions of microorganisms living in your gut—and they might just be the key to helping treat diseases like Crohn’s and ulcerative colitis. Meet a researcher who spends her days exploring this microscopic world.

If getting healthy is one of your resolutions—and you’ve wondered about bariatric surgery—here are answers to some common questions, including what BMI you really need to have to qualify for the procedure and whether you can expect to gain any weight back.

Tackling a triathlon isn’t for the faint of heart. But Mark van Ooij, an Associate Scientific Director for Janssen Vaccines & Prevention B.V., is doing just that—and he’s taking what he’s learned from his disease to propel him forward.